Literature DB >> 32080350

Clinicopathological characteristics of glomeruloid architecture in prostate cancer.

Eva Hollemans1, Esther I Verhoef2, Chris H Bangma3, John Rietbergen4, Susanne Osanto5, Rob C M Pelger6, Tom van Wezel7, Henk van der Poel8, Elise Bekers9, Jozien Helleman3, Monique J Roobol3, Geert J L H van Leenders2.   

Abstract

Glomeruloid architecture is the least common Gleason 4 growth pattern in prostate adenocarcinoma. Its clinicopathological features and relation with cribriform architecture, which has been recognized as an adverse feature, remains to be established. Our objective was to investigate clinicopathological features of glomeruloid architecture in radical prostatectomies. We reviewed 1064 radical prostatectomy specimens and recorded Grade Group, pT-stage, margin status, Gleason pattern percentages, and growth patterns. Simple and complex glomerulations were distinguished by gland size and intraluminal cribriform protrusions. Clinical endpoint was biochemical recurrence-free survival. Glomerulations were identified in 365 (34%) specimens. In 472 Grade Group 2 patients, 210 (44%) had simple and 92 (19%) complex glomerulations. Complex glomerulations coincided with cribriform architecture more often than simple glomerulations (67% versus 52%; P = 0.01). Men with simple glomerulations had significantly lower prostate specific antigen (PSA) levels (9.7 versus 12.1 ng/ml; P = 0.03), percentage Gleason pattern 4 (19% versus 25%; P = 0.001), extra-prostatic extension (34% versus 50%; P = 0.01), and positive surgical margins (25% versus 39%; P = 0.04) than those with cribriform architecture. Extra-prostatic extension (37%) and positive surgical margins (30%) in men with complex glomerulations resembled those with simple glomeruloid rather than those with cribriform architecture. In multivariate Cox regression analysis adjusted for PSA, pT-stage, margin status, and lymph node metastases, cribriform architecture had independent predictive value for biochemical recurrence-free survival (hazard ratio (HR)) 1.9; 95% confidence interval (CI) 1.2-2.9; P = 0.004), while simple (HR 0.8; 95% CI 0.5-1.2; P = 0.26) and complex (HR 0.9; 95% CI 0.5-1.6; P = 0.67) glomerulations did not. Both simple and complex glomeruloid architecture are associated with better outcome than cribriform architecture in Grade Group 2 prostate cancer patients. Therefore, glomeruloid pattern and particularly complex glomerulations should not be classified as a cribriform growth pattern variant in radical prostatectomy specimens.

Entities:  

Mesh:

Year:  2020        PMID: 32080350     DOI: 10.1038/s41379-020-0507-2

Source DB:  PubMed          Journal:  Mod Pathol        ISSN: 0893-3952            Impact factor:   7.842


  3 in total

1.  Classification of prostatic carcinomas.

Authors:  D F Gleason
Journal:  Cancer Chemother Rep       Date:  1966-03

Review 2.  The 2014 International Society of Urological Pathology (ISUP) Consensus Conference on Gleason Grading of Prostatic Carcinoma: Definition of Grading Patterns and Proposal for a New Grading System.

Authors:  Jonathan I Epstein; Lars Egevad; Mahul B Amin; Brett Delahunt; John R Srigley; Peter A Humphrey
Journal:  Am J Surg Pathol       Date:  2016-02       Impact factor: 6.394

Review 3.  Active surveillance and focal therapy for low-intermediate risk prostate cancer.

Authors:  Laurence Klotz
Journal:  Transl Androl Urol       Date:  2015-06
  3 in total
  2 in total

1.  Prostate cancer growth patterns beyond the Gleason score: entering a new era of comprehensive tumour grading.

Authors:  Geert J L H van Leenders; Esther I Verhoef; Eva Hollemans
Journal:  Histopathology       Date:  2020-09-13       Impact factor: 5.087

2.  Analysis of separate training and validation radical prostatectomy cohorts identifies 0.25 mm diameter as an optimal definition for "large" cribriform prostatic adenocarcinoma.

Authors:  Emily Chan; Jesse K McKenney; Sarah Hawley; Dillon Corrigan; Heidi Auman; Lisa F Newcomb; Hilary D Boyer; Peter R Carroll; Matthew R Cooperberg; Eric Klein; Ladan Fazli; Martin E Gleave; Antonio Hurtado-Coll; Jeffry P Simko; Peter S Nelson; Ian M Thompson; Maria S Tretiakova; Dean Troyer; Lawrence D True; Funda Vakar-Lopez; Daniel W Lin; James D Brooks; Ziding Feng; Jane K Nguyen
Journal:  Mod Pathol       Date:  2022-02-10       Impact factor: 8.209

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.